Ketogenic Diet May Affect Glioma Outcomes

July 12, 2017

There are a number of reasons why people maintain a low-sugar diet, including lowering body fat and decreasing their risk of developing type 2 diabetes. But now, patients with gliomas might have another reason to add to their list: potentially having better cancer outcomes from cutting the sweetness.
Recently, a group of researchers from Massachusetts General Hospital (MGH) conducted a systemic review to see if ketogenic metabolic therapy (KMT) would be safe and effective in treating patients with malignant gliomas.
“Despite many decades of research, malignant glioma — the most common type of primary brain cancer — still carries a poor prognosis and there is a pressing need for identifying and implementing more efficacious therapies,” two of the authors, Sebastian F. Winter, B.Sc., visiting doctoral researcher at the Neuro-Oncology Program at MGH Cancer Center, Harvard Medical School, and Jorg Dietrich, M.D., Ph.D., clinical director of the Cancer and Neurotoxicity Clinic and Brain Research Program at MGH, said in an interview with CURE.

Click HERE to read the full article by Brielle Urciuoli in CURE Magazine